Shares of Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report) have earned a consensus rating of "Buy" from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $144.00.
A number of research analysts recently commented on KRRO shares. Oppenheimer assumed coverage on Korro Bio in a research note on Friday, January 10th. They issued an "outperform" rating and a $155.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $115.00 target price on shares of Korro Bio in a research note on Friday, November 22nd. Raymond James initiated coverage on shares of Korro Bio in a report on Monday, October 21st. They issued a "strong-buy" rating and a $153.00 price objective for the company. William Blair reaffirmed an "outperform" rating on shares of Korro Bio in a report on Wednesday, November 13th. Finally, Royal Bank of Canada boosted their price target on shares of Korro Bio from $95.00 to $105.00 and gave the stock an "outperform" rating in a research note on Monday, October 21st.
View Our Latest Analysis on Korro Bio
Insider Activity
In other news, CFO Vineet Agarwal sold 800 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $70.00, for a total value of $56,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 5.40% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC raised its holdings in Korro Bio by 38.3% in the 2nd quarter. Millennium Management LLC now owns 84,201 shares of the company's stock worth $2,852,000 after acquiring an additional 23,307 shares during the last quarter. Quest Partners LLC lifted its holdings in shares of Korro Bio by 172.1% during the third quarter. Quest Partners LLC now owns 1,777 shares of the company's stock valued at $59,000 after purchasing an additional 1,124 shares in the last quarter. Brown Brothers Harriman & Co. lifted its holdings in shares of Korro Bio by 251.0% during the third quarter. Brown Brothers Harriman & Co. now owns 2,854 shares of the company's stock valued at $95,000 after purchasing an additional 2,041 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Korro Bio by 1,018.2% during the third quarter. BNP Paribas Financial Markets now owns 4,909 shares of the company's stock valued at $164,000 after buying an additional 4,470 shares during the last quarter. Finally, MetLife Investment Management LLC increased its holdings in Korro Bio by 129.0% in the 3rd quarter. MetLife Investment Management LLC now owns 3,639 shares of the company's stock worth $122,000 after buying an additional 2,050 shares in the last quarter. Institutional investors own 13.18% of the company's stock.
Korro Bio Stock Performance
Shares of NASDAQ:KRRO traded down $0.06 on Wednesday, hitting $34.12. The company's stock had a trading volume of 57,183 shares, compared to its average volume of 82,922. Korro Bio has a 1 year low of $30.00 and a 1 year high of $98.00. The company has a 50-day simple moving average of $42.00 and a 200 day simple moving average of $45.69.
Korro Bio (NASDAQ:KRRO - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($2.26) earnings per share for the quarter, beating analysts' consensus estimates of ($2.55) by $0.29. As a group, equities analysts predict that Korro Bio will post -9.52 EPS for the current fiscal year.
Korro Bio Company Profile
(
Get Free ReportKorro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
Featured Stories
Before you consider Korro Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Korro Bio wasn't on the list.
While Korro Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
